LOI Coversheet CRI Clinical Innovator Grant

Principal Investigator:

| Prefix | First Name | M.I | l. | Last Nam | ne | Suffix | | |
|--------------------------------------|------------|---|---|---|-------------------------------|--------|--|--|
| Institution Nar | ne: | | | | | | | |
| | | Study | Informatio | n: | | | | |
| Study Title: | | | | | | | | |
| IND Sponsor: | | | | | | | | |
| Trial Phase: _ | | | hybrid phas Ise list: | se, | | | | |
| Protocol IRB Approval State | •• | | | | | | | |
| Indications: | | | Intervent List drugs access sto commerco available, access se be secure | s and drug atus (e.g. ially drug ecured, to | | | | |
| Site(s): | | | _ Collabora If any | itors: | | | | |
| L | | Stud | dy Timing: | | | | | |
| Estimated Trial Activation Date: | | Month/Day/Year | Requested Duration of Support: | | No. of Years | | | |
| Estimated First Patient, First Visit | | Estimated Last Patient, Last Visit Month/Day/Year | | | Month/Day/Year | | | |
| Financial Information: | | | | | | | | |
| Total Study Cost: | | Estimated Clinical Budget: | | | Estimated Correlat Budget: | ive | | |

Additional Funding Sources (if applicable):

| Source | Amount | Funding Status |
|--------|--------|----------------|
| | | |
| | | |
| | | |
| | | |